USCOM LIMITED — AGM Information 2021

Oct 13, 2021

PRESENTATION AND UPDATE

Uscom AGM 21

ASX: UCM Prof. Rob Phillips Chairman and CEO, Uscom Limited

October 14,2021

Summary

Uscom Vision

“Building a world leading medical technology enterprise combining lifesaving cardiovascular and pulmonary technologies that establish new standards of medical excellence and global academic recognition, with sustainable profits.”

Prof. Rob Phillips

2 | Motivated by Vision, Driven by Fundamentals

Uscom Overview

ASX Listed

Global cardiovascular and pulmonary medical technology Visionary and innovative corporate culture

Profit and Cash Flow

Profit & Cash Flow +ve China and Europe, Cash in bank and debt free

High Growth and Margins

9 year: total receipts up 535% and 24% CAGR. Huge global addressable markets – 75% of all mortality

==> picture [57 x 56] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 56] intentionally omitted <==

==> picture [57 x 56] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 56] intentionally omitted <==

Global Vision and Ambitions

Sydney, Singapore, Beijing, Budapest, Auckland, London, LA. Actively pursuing growth and scale

Patented Apex Technologies

World leading digital medical technologies, >200 IP submissions Strong IP and R&D supported product pipeline

New Products

New global distribution, products and approvals for FY22 – up 140%

3 | “Fast growing, sound fundamentals, global vision, expanding patented technologies to drive new growth.”

Uscom Snapshot

Uscom is an established medical technology enterprise preparing for a growth inflection with a global footprint and an expanding international network of operations acting as hubs for new distributors

==> picture [31 x 31] intentionally omitted <==

7 Global centres Expanding distribution hubs

annual AUD$5.6m 2 Manufacturing sites across 7 countries receipts (FY21) Australia China Hungary Singapore UK

==> picture [34 x 35] intentionally omitted <==

US

==> picture [42 x 42] intentionally omitted <==

1,500[+]

USCOM 1A units installed globally

• LA

• London • Budapest

• Beijing

24% p.a. the last 9 yearsCAGR over

==> picture [46 x 46] intentionally omitted <==

• Singapore

Years in business 20[+] since 1999

==> picture [46 x 46] intentionally omitted <==

• Sydney

==> picture [38 x 38] intentionally omitted <==

IP submissions 200[+] protecting Uscom devices and technology

• Auckland

4 | Persistence, Diligence, Excellence and Achievement

Digital Technology

==> picture [153 x 153] intentionally omitted <==

==> picture [6 x 5] intentionally omitted <==

==> picture [97 x 12] intentionally omitted <==

----- Start of picture text -----

U S C O M 1 A
----- End of picture text -----

USCOM 1A software Uscom Advanced Haemodynamic APP Heart failure, hypertension, sepsis, fluid

==> picture [255 x 163] intentionally omitted <==

==> picture [168 x 27] intentionally omitted <==

----- Start of picture text -----

BP+ Reporter
Hypertension, vascular health
----- End of picture text -----

Devices addressing diseases responsible for 75% of global mortality

==> picture [219 x 119] intentionally omitted <==

==> picture [147 x 45] intentionally omitted <==

SpiroReporter SpiroAPP Asthma, COPD, OLD and COVID

==> picture [152 x 38] intentionally omitted <==

==> picture [59 x 48] intentionally omitted <==

==> picture [205 x 124] intentionally omitted <==

==> picture [120 x 60] intentionally omitted <==

----- Start of picture text -----

Blue Sky
Uscom eHealth Ecosystem
----- End of picture text -----

==> picture [58 x 48] intentionally omitted <==

VENTITEST-S Ventilator testing

==> picture [97 x 33] intentionally omitted <==

----- Start of picture text -----

Blue Sky
Uscom eHealth Ecosystem
----- End of picture text -----

5 | Digital Products

Global Health

Uscom - part of the global health solution

==> picture [179 x 135] intentionally omitted <==

✓ ✓ ✓ ✓ ✓

- WHO Top 10

==> picture [219 x 118] intentionally omitted <==

✓

✓

Note: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

6 | Addressing Global Disease

Growth Markets

High value technologies in large markets with strong predicted growth

$21.6B USD 5yr CAGR 4.8%

==> picture [227 x 171] intentionally omitted <==

$1.4B USD 7yr CAGR 11.2%

==> picture [274 x 171] intentionally omitted <==

$1.3B USD 5yr CAGR 8.16%

==> picture [256 x 138] intentionally omitted <==

USCOM 1A

The Global Cardiac Monitoring & Cardiac Rhythm Management Market is estimated to increase from $21.6B HSD in 2020 to $27.31B USD by 2025, at a CAGR of 4.8%.

Heart failure, Sepsis, Fluid management, COVID

BP+

The global BP monitoring devices market is $1.4B USD and is expected to reach $3.24B USD by 2028 at a CAGR of 11.2%.

Hypertension, Vascular health

SpiroSonic AIR

The global spirometer market is expected to grow rom $1.269B USD in 2019 to $2.198B USD in 2026 at a CAGR of 8.16%.

Asthma, COPD, OLD, COVID

Note: Researchandmarkets

7 | Massive Markets and Rapid Growth

eHealth Technology

==> picture [252 x 162] intentionally omitted <==

----- Start of picture text -----

U S C O M 1 A
----- End of picture text -----

USCOM 1A software Uscom Advanced Haemodynamic APP

==> picture [138 x 138] intentionally omitted <==

==> picture [79 x 47] intentionally omitted <==

BP+ Reporter

Frontiers in Digital Health technology

==> picture [613 x 248] intentionally omitted <==

----- Start of picture text -----

data data
SpiroReporter
SpiroSonic APP
Blue Sky
Uscom eHealth Ecosystem
----- End of picture text -----

==> picture [151 x 37] intentionally omitted <==

data data Cascade of Revenue AI, Meta Data, Licensing, Cloud services, Pay per use, Rental, Subscription, Partnerships, Data licensing/sale/research, Third party rentals for access to the “Ecosystem”

VENTITEST-S

Note: Researchandmarkets

8 | eHealth the Future

eHealth Growth

eHealth

Market forecast to grow at CAGR of 19.4%

==> picture [331 x 285] intentionally omitted <==

----- Start of picture text -----

$250.00
USD 206.3 Billion
$200.00
$150.00
$100.00
USD 59.5 Billion
$50.00
$0.00
2020 2027
USD $Billion
----- End of picture text -----

==> picture [220 x 76] intentionally omitted <==

----- Start of picture text -----

Blue Sky
Uscom eHealth Ecosystem
----- End of picture text -----

• eHealth is a health delivery revolution

• Uscom is committed to eHealth

• BlueSky eHealth expected to underwrite Uscom growth foreseeably

• First revenue for 2[nd] half FY22

9 | eHealth Growth

Note: Researchandmarkets

FY21 Results

==> picture [382 x 323] intentionally omitted <==

----- Start of picture text -----

6.00
5.58
5.00
4.55 4.60
4.28
3.85
4.00
3.48
3.00
2.00
1.00
0.00
Profit Cash Flow Sales Revenue Cash
-1.00 -0.87 -0.34 -0.16 Receipts
-1.33
-2.00
$m AUD
----- End of picture text -----

FY20 FY21

==> picture [212 x 208] intentionally omitted <==

==> picture [263 x 214] intentionally omitted <==

Continued Growth

Sales, revenue and cash receipts growth, and first ever positive annual operating cash flow.

First year of cash receipts greater than $5.5m despite being a difficult trading year beset by intermittent lockdowns and travel restrictions.

China and Europe profitable

Sales by Product / Region

China - major Uscom market. USCOM 1A - lead product

This will shift as regulatory approvals are received for BP+ and SpiroSonic devices

10 | Sales, Revenue, Cash Growth

Sustained Growth

==> picture [649 x 390] intentionally omitted <==

----- Start of picture text -----

$0.86m $2.94m $5.58m
FY2012 UCM FY2016 UCM FY2021 UCM
Total cash receipts Total cash receipts Total cash receipts
$6.00
$5.00 5.46
4.6
$4.00
3.64
$3.00 $3.50
$2.94 2.86
$2.00
$2.04
$1.00 $1.38
$1.01
$0.86
$0.00
$m AUD
----- End of picture text -----

• Total cash receipts $5.58m, up 21% from $4.60m

• • First ever cash receipts

• $5.5m

• 9 year total cash receipts trend growth

• 535% total increase

• 24% pa compound annual growth

11 | Trend Growth

New Regulatory

New approvals = new sales = new revenue All Uscom devices received new approvals in major jurisdictions in FY21

==> picture [482 x 307] intentionally omitted <==

==> picture [150 x 150] intentionally omitted <==

==> picture [308 x 306] intentionally omitted <==

12 | Regulatory News

Global Approvals

Regions

7 New Approvals for FY22 up from 5 (up 140%)

Approvals

==> picture [161 x 222] intentionally omitted <==

----- Start of picture text -----

China
SE Asia
Europe
US
----- End of picture text -----

==> picture [245 x 228] intentionally omitted <==

==> picture [475 x 288] intentionally omitted <==

----- Start of picture text -----

China SE Asia Euro US Russia ROW
U S C O M ✓
1 A
2021
✓ ✓ ✓ 2022
✓ ✓ ✓
Pending
✓ ✓ ✓
✓ ✓ ✓
✓ New Approvals
----- End of picture text -----

Russia 13 | New Products and New Regions

Regulatory Lift

7 new approvals for USCOM 1A, BP+, SpiroSonic for FY22

==> picture [510 x 365] intentionally omitted <==

14 | More Products, Distributors, Sales and Revenue

USCOM 1A

==> picture [688 x 376] intentionally omitted <==

• 1500[th] USCOM 1A Manufactured

• ~$30m USD

• 400 peer reviewed papers

• Life saving, standard of care

• COVID, Sepsis, heart failure, fluid, hypertension, preeclampsia

• Neonates, children and adults

• Installed in top hospitals worldwide

15 | Standard of Care USCOM 1A

COVID and Uscom

==> picture [314 x 182] intentionally omitted <==

Reference: https ://www.healtheuropa.eu/post-covid-syndromeafter-the-pandemic-the-pulmonary-consequences/109373/

==> picture [317 x 171] intentionally omitted <==

COVID – USCOM 1A

• COVID - Lung virus which attacks cardiovascular system

• Patients mostly die from cardiovascular failure

• USCOM 1A best device for rapid CV monitoring and therapy

• USCOM 1 – recommended by China NHMC for severe COVID treatment

==> picture [213 x 170] intentionally omitted <==

• 50 new China infectious disease centres commissioned with

USCOM 1A

Post-COVID Syndrome – SpiroSonic AIR

• ~2B people infected by COVID

• Many develop pulmonary fibrosis during or after

• Require home lung monitoring for diagnosis/treatment

• Spirometry market to increase ~160% over 6 years - $2.6B to $6.5B

• SpiroSonic AIR -most advanced digital ultrasonic spirometry

16 | Uscom Devices for COVID

SpiroSonic AIR

“Hospital in Home” – Asthma, COVID, COPD and OLD The SpiroSonic AIR Cycle – a wireless connection of data, information, diagnosis and reports generating a cascade of revenue

eHealth Revenue Cascade

• Device sale

• APP Sale

• Software sale

• • Cloud storage - Big data

• AI analysis

• Clinician diagnosis

• Prescription

• Report

• System subscription

==> picture [538 x 390] intentionally omitted <==

17 | SpiroSonic AIR Cycle Hospital in Home

VentiTest

The SpiroSonic VentiTest is a patent protected digital multi-path ultrasonic ventilator testing and calibration solution which incorporates:

==> picture [39 x 38] intentionally omitted <==

==> picture [37 x 37] intentionally omitted <==

Low resistance

High resolution

bi-directional digital multipath acoustic flow monitor

Pressure module to control piezoresistive monolithic silicon pressure sensors

==> picture [38 x 39] intentionally omitted <==

==> picture [38 x 38] intentionally omitted <==

Test lung simulator

“Weather station”

Provides variable elasticity and compliance and variable leak function to simulate the patient circulation

module for calibration of ambient temperature, pressure and humidity changes

==> picture [202 x 50] intentionally omitted <==

==> picture [141 x 237] intentionally omitted <==

==> picture [322 x 193] intentionally omitted <==

Protecting against Ventilator Induced Lung Injury – “VILI” Ventilator market $4.2B USD, with 14.7% pa growth I VentiTest per 10 ventilators

18 | Ventilator Calibration VENTITEST

Global Specialisation

Transitioning to a complex global organisation requires specialised operational divisions within the company to support efficient growth and expansion

Finance and Management

Each region accounts and reports independently and to HQ

Manufacturing

Cost effective organisation for global manufacturing of all our products

==> picture [178 x 119] intentionally omitted <==

==> picture [177 x 119] intentionally omitted <==

==> picture [174 x 88] intentionally omitted <==

==> picture [180 x 88] intentionally omitted <==

Marketing, Sales and Distribution

Global coordination of branding, messaging, clinical sales materials, education and training, forecasting and result monitoring

R&D

Develop IP and concepts for new products

19 | Global Efficiency Specialisation

New Technology R&D

==> picture [533 x 379] intentionally omitted <==

World leading science Invasive validation of BP+ waveforms

==> picture [324 x 202] intentionally omitted <==

BP+ Reporter Hypertension, vascular health

20 | Life Saving Science

China Recognition

“Building a Global Business”

==> picture [353 x 238] intentionally omitted <==

Uscom China Listed as China National High Technology Enterprise by PRC Ministry of Science and Technology

==> picture [336 x 238] intentionally omitted <==

Uscom China ranked AAA Credit Enterprise by China Credit Enterprise Publicity Network

21 | China Recognition for Excellence

Regional Strategy

==> picture [281 x 42] intentionally omitted <==

----- Start of picture text -----

Australia China Hungary Singapore UK US
----- End of picture text -----

Uscom China

More, bigger and better distribution, prepare BP+ and SpiroSonic marketing and distribution, and develop domestic manufacture

Uscom Europe

Growing manufacturing capacity to meet demand and increasing distribution and sales for USCOM 1A, BP+ and SpiroSonic

Uscom SE Asia

Singapore based regional distribution and regulatory hub for USCOM 1A, SpiroSonic and BP+

Uscom US

Activate new distribution model to meet post pandemic demand and prepare for SpiroSonic and BP+

==> picture [444 x 516] intentionally omitted <==

22 | Regional Strategy Expanding

Achievements and Plans

A transformational year for Uscom Limited

FY21 – Performance and Investment

Operations

Results

3 new Product Approvals 2 Approvals Pending 1500[th] 1A Unit Sale Global Distribution Growth New Regional HQ ~200 IP Approvals and Submissions

Operating Cash Positive China Profit Europe Profit Total Receipts $5.6m Cash on hand Debt Free

FY22 –Growth and Profit

Operations

Strategy

Address Parlous Investor Value Continue Growth New products New Distribution Strategic Partnerships Post COVID Applications Global Recovery

Grow Revenue/Profit eHealth opportunities Expand Distribution New Manufacturing New R&D Centre Rationalisation for Profit

==> picture [480 x 540] intentionally omitted <==

23 | Growth Transforming Uscom

Growth and Profit

The year ahead

FY22 - Growth & Profit.

==> picture [169 x 141] intentionally omitted <==

----- Start of picture text -----

Growth & Profit
----- End of picture text -----

We have invested in the future, and our next steps to are to combine our vision, culture, people, organisation, products, sales and global strategy to deliver growth and sustainable profit;

==> picture [405 x 176] intentionally omitted <==

----- Start of picture text -----

Products Sales
Global Strategy Organisation
----- End of picture text -----

Culture and People Vision and Mission

24 | Invested in the Future

Summary

FY21 – Performance and Investment

“FY21 was a very good year for Uscom, with continued Strong revenue growth, Operating cash flow positivity, China profit, Europe profit and Multiple device approvals.”

FY22 – Growth and Profit

“We plan expansion and growth, with new manufacturing – global efficiency and meet demand, new R&D initiatives, operational restructure – enhanced profit, and a strategic corporate review to identify growth opportunities.”

Prof. Rob Phillips

25 | Strong Growth and investment for Future

PRESENTATION AND UPDATE Thank You ASX: UCM Prof. Rob Phillips Chairman and CEO, Uscom Limited

October 14,2021

==> picture [681 x 455] intentionally omitted <==

Corporate Responsibility

==> picture [631 x 410] intentionally omitted <==

----- Start of picture text -----

UCM – Investor Presentation April 2020
----- End of picture text -----

Uscom supports the Australian Wildlife Conservancy.

in the last 15 years Australia's threatened species list has increased by 36%. 87% of our mammal species, 93% of reptiles, 94% of frogs and 45% of our bird species are found only in Australia.

AWC is committed to reversing Australia’s record as the world’s mammalian extinction capital.

• AWC conserving the Northern Quoll at Fish River Station in Queensland

27 | Australian Wildlife Conservancy

Rob Phillips personally contributes to AWC on behalf of Uscom